317810-73-4

Basic information

• Product Name: 3-Pyridinamine,6-(difluoromethoxy)-(9CI)
• Synonyms: 3-Pyridinamine,6-(difluoromethoxy)-(9CI);6-Difluoromethoxy-pyridin-3-ylamine
• CAS NO: 317810-73-4
• Molecular Formula: C₆H₆F₂N₂O
• Molecular Weight: 160.12
• Product Categories: METHOXY
• Mol File: 317810-73-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-Pyridinamine,6-(difluoromethoxy)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinamine,6-(difluoromethoxy)-(9CI)(317810-73-4)
• EPA Substance Registry System: 3-Pyridinamine,6-(difluoromethoxy)-(9CI)(317810-73-4)

Safety Data

• Hazardous Substances Data: 317810-73-4(Hazardous Substances Data)

Usage

General Description

3-Pyridinamine, 6-(difluoromethoxy)-(9CI) is a chemical compound with the molecular formula C6H6F2N2O. It is also known by its CAS number 2520-79-4. 3-Pyridinamine,6-(difluoromethoxy)-(9CI) is a derivative of pyridine and contains a fluoromethoxy group. It is used in the pharmaceutical and chemical industries as a building block and intermediate in the synthesis of various organic compounds. Additionally, it has potential applications in medicinal chemistry and drug discovery due to its unique chemical structure and properties. However, further research and studies are required to fully understand its potential uses and effects.

Upstream product

• 5418-51-9 5-nitro-2-hydroxypyridine 
• 1192813-41-4 2-(difluoromethoxy)-5-nitropyridine 

Relevant articles and documents

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Tricyclic Compounds As mPGES-1 Inhibitors

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.